Startup Instructors

AUTM Annual Meeting

Startup Course Instructors

Keith Marmer serves as chief innovation & economic engagement officer at the University of Utah. In this role, Keith has transformed the culture of commercialization at University of Utah, launching three accelerators, a business incubator and a venture fund to support startup companies, facilitating the creation of 52 companies, and generating more than $60 million in university revenue from licensing and industry collaborations. His strong leadership skills come from 30 years of experience as an inventor, entrepreneur and investor. He has three patents, launched three companies, and helped entrepreneurs raise more than $1 billion in investment capital. Previously, Keith was co-founder and managing director of SG3 Ventures, a venture capital fund focused on early-stage life science companies. Prior to SG3 Ventures, Keith was chief business officer at Penn Center for Innovation, University of Pennsylvania. Before his university-based commercialization roles, he was an entrepreneur, founding and scaling two companies and co-founding a consulting firm that advised early-stage growth companies. Across his career, Keith has launched, help to launch or overseen teams responsible for starting more than 140 companies. Keith serves, and has served on numerous corporate and non-profit boards and is a past entrepreneur-in-residence at Princeton University. He received an MBA, Doctor of Physical Therapy, Master of Physical Therapy and Bachelor of Science in Health Sciences from University of the Sciences.

Mostafa Analoui, Ph.D., is Executive Director of Venture Development and Technology Incubation Program (TIP) at UConn. Previously, he was Head of Healthcare and Life Sciences at Livingston Securities (New York, NY) with investment focus in private and public companies in biotech, medtech and healthcare services. Prior to that, he was the Senior Director at Pfizer Global Research and Development. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies.

Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.

Dr. Analoui has authored over 130 publications, including journal articles, a book and book chapters and technical reports. He was Chairman of the Board of VirtualScopics (NASDAQ: VSCP) and currently serves as Chairman of the Board member of Cyclica, member of the board of Connecticut Innovations, and NanoBusiness Commercialization Association.

Douglas Hockstad is TLA's Assistant Vice President. TLA helps to accomplish the broader University of Arizona mission by providing a variety of services to faculty that protect intellectual property, streamline the technology commercialization process, support the creation of startups based on University technology, and find commercial applications for university research. Doug joined the UA with 25 years’ of experience in high tech markets, primarily in the software market, including both established company and startup experience, and most recently having served as Associate Director, Software & Engineering Licensing in the University of Michigan's Office of Technology Transfer. In this role, along with his primary responsibility for managing software and other copyright-related intellectual property created across the entire U of M campus, he also managed the office's information technology requirements, and served as the liaison between the Office of Tech Transfer and the College of Engineering.

Rick Huebsch is Executive Director for the University of Minnesota’s Technology Commercialization team, which is responsible for all facets of technology transfer including IP protection, marketing, licensing, and startups through the Venture Center.  In addition, his team partners with the UMN Foundation on the University's Corporate Engagement initiatives. He also serves on the Launch  Advisory Board for the State of Minnesota. Rick joined the University in 2008 after 20 years of software industry experience including roles in software engineering, technology strategy, and executive management with Minnesota and California software companies.

Shintaro Kaido is Vice Provost for Innovation and Executive Director, Drexel Applied Innovation at Drexel University. As Drexel's inaugural Vice Provost for Innovation, Shintaro works with Drexel's senior leadership to chart the future course of Drexel's innovation ecosystem. As Executive Director of Drexel Applied Innovation, Shintaro leads a team of ten professionals to expand the impact of Drexel research through tech transfer. Shintaro is a member of the Kauffman Fellows, a highly selective, global fellowship of top venture capital professionals and is the first in the Fellowship's 26-year history to be from academic tech transfer.

Nichole Mercier, PhD, is the Assistant Vice Chancellor for Washington University in St. Louis & the Office of Technology Management’s Managing. Dr. Mercier started her career in tech transfer at Boston Children’s Hospital before moving to St. Louis in 2005 as a member of OTM’s licensing team. In addition to leading tech transfer, she is dedicated to improving how underserved academic innovators participate in commercializing research. She developed and instituted WashU’s Women in Innovation and Technology (WIT) program to engage female innovators in technology transfer, and in 2020, she created the national event, Equalize, to empower academic women in entrepreneurship.

Stephen Nappi has been in the business of commercializing university discoveries for the past 20 years. Mr. Nappi joined Temple University in 2008 as its Director of Technology Transfer and he currently serves as Associate Vice President of Technology Commercialization and Business Development within the Office of the Vice President for Research. In that role, Mr. Nappi heads the university’s efforts to identify, protect and commercialize research-based discoveries while growing an ecosystem to support technology acceleration and startup creation.

At Temple, Mr. Nappi benefits from a growing research environment that has led to the creation of over 35 startup companies in the past 10 years. These companies have successfully launched 5 products and collectively raised more than $160M in funding in the past 2 years. To support the university’s startup portfolio, Mr. Nappi contributed to the formation of seed and venture-stage investment programs. Prior to joining Temple, Mr. Nappi spent 7 years at Florida Atlantic University in its Office of Technology Transfer.

Mr. Nappi holds a BBA in business management and marketing from Florida Atlantic University. He is a member of AUTM and the Licensing Executive Society. Mr. Nappi is President Emeritus of BioStrategy Partners and continues to serve on its Board of Directors.

Jim O’Connell is the Assistant Vice President of Commercialization, and Director of Tech Transfer, responsible for commercializing and translating UF technologies into the marketplace as well as all startup activity and its two world class business incubators. Jim has a broad background in business and product development as well as an extensive technology transfer experience from the University of Michigan and the University of Miami. He also has large corporate experience from Stryker Instruments, as well as startup experience from Xoran Technologies and Sensicore. In his more than 20 years in industry, Jim’s roles have always focused on growing and establishing businesses while commercializing new, high tech products, with both operations and engineering responsibilities. He has helped commercialize over 35 different products including biomaterials, RF Ablation devices, infusion pumps, surgical power tools, high volume sterile disposables, CT Scanners, surgical navigation systems, resorbable plates and screws, and amperometric electrochemical sensors and is also a patented inventor. He has a BS in Aeronautical Engineering from Rensselaer and an MS in Engineering Management from the University of Maryland. Prior to industry, Jim was a helicopter pilot in the U.S. Air Force.

Mike Psarouthakis leads the Innovation Partnerships Venture Center working with U-M faculty, staff and students on new company formation based on intellectual property discovered and developed at the University of Michigan’s 19 schools. He will also manage the investment activity of the Accelerate Blue Fund. Mike has over 30 years of entrepreneurial, senior management and venture fund experience in both the public and private sectors.

Before joining the University of Michigan, Mike was the Vice President of Business Acceleration at the Michigan Economic Development Corporation where he oversaw a $250 million portfolio of investments in over 150 early stage technology companies. Prior to the MEDC he was an Assistant Vice President at Forest Health Services where he managed a $50 million corporate venture fund that focused on life sciences, IT and manufacturing opportunities.

Mike has directed several successful company exits and is the founder of four companies. He has served on numerous profit and non-profit boards and advisory boards including; eBay, PayPal, Compendia Biosciences, Online Technologies, the College of Creative Studies in Detroit, and the Ann Arbor Local Development Financial Authority. He remains very active in the Michigan startup community working with Invest Michigan, Ann Arbor SPARK, Invest Detroit, Accelerate Michigan Innovation Competition, Great Lakes Entrepreneur’s Quest, TechArb, DTE Energy Business Plan Competition and many others.

Mike earned his MBA with concentrations in corporate strategy and marketing and MS in natural resource management from the University of Michigan. He also holds a BS in history and political science from Eastern Michigan University.

Teri Willey returned to Indiana in 2018 to join Indiana University as an Executive Director of IU Ventures and to launch and manage the new Indiana Philanthropic Venture Fund. She is a member of the IU Ventures Board and Investment Committee; Dimension Mill/Velocities Investment Committee; a Director of the Venture Club of Indiana, a Director of portfolio companies NERx Biosciences, Diagnotes and Periodic, and an Advisor to OnCode Institute in the Netherlands.

Teri served as Vice President of Cold Spring Harbor Laboratory leading a new program for industry engagement, new ventures and intellectual property licensing; Vice President for Technology and Business Development for Mount Sinai School of Medicine; founding Chief Executive of Cambridge Enterprise, Ltd the technology commercialization affiliate of the University of Cambridge in England; founder and Managing Partner of ARCH Development Partners (ADP), a seed and early stage venture fund focused on university and corporate spin-outs; Business Development for Endocyte, Inc., University of Notre Dame Business School Adjunct Faculty; and Vice President of Start-ups at ARCH Development Corporation, a subsidiary of the University of Chicago, which commercialized technology from the University and Argonne National Laboratory. Her prior experience also includes non-executive board positions with a several early stage companies and technology transfer leadership roles at Northwestern University and Purdue Research Foundation. Teri has been an advisor to policy makers, universities and companies, is a past President of AUTM, a former Bye Fellow of Christ’s College Cambridge in England and a Sagamore of the Wabash.



Annual Meeting Sponsors

NIIMBL
Parker Highlander PLLC
PhRMA
Merck
Amster, Rothstein & Ebenstein LLP
KPPB
LifeArc
Osage University Partners
Wellspring
Blank Rome LLP
Novartis
Casimir Jones, SC
Computer Packages, Inc.
LockeLord
MPEG LA LLC
Royalty Pharma
Schwegman Lundberg & Woessner
Quarles & Brady LLP
Boehringer Ingelheim Pharmaceuticals Inc.
Marshall Gerstein
Bereskin & Parr LLP
Baker Donelson
Cayuse
Thomas Horstemeyer LLP
RWS
DocuSign
Berggren
DRI Capital
KISSPlatform Europe BV